Phase 2 Start
WOK: Phase 2 Start: A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy
November 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 1, 2026
- Company
- WORK Medical Technology Group LTD (WOK)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Randomized, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy
- Indication
- Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera; Myelofibrosis; Anemia